Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CYCLOCORT is a topical ointment small-molecule corticosteroid approved in 1981 for dermatological indications. The exact mechanism of action and specific approved indications are not publicly detailed in available data, but topical corticosteroids generally work by reducing inflammation and immune response in skin conditions. This is a mature, legacy product in the Astellas portfolio.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), this brand is likely in managed decline with a lean, efficiency-focused team.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
CYCLOCORT offers limited career growth opportunities as a legacy product with zero linked job openings and approaching loss of exclusivity. Roles on this product are primarily defensive commercial positions focused on volume protection and margin optimization rather than market expansion or innovation.
Worked on CYCLOCORT at Astellas? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.